Researchers at the Tufts Lyme Disease Initiative recently received grants totaling more than $7 million to build on an already impressive array of discoveries that Tufts’ teams have made to combat tick-borne diseases.
Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate – Biotech Investments
EQS-News: Formycon AG / Key word(s): Regulatory Admission/Miscellaneous Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202,